Panacea Biotec Ltd. Share Price

Panacea Biotec Wins ₹78.24 Cr UNICEF Award for Bivalent Oral Polio Vaccine Supply

has received a Letter of Award from UNICEF for the supply of bivalent oral polio vaccine (bOPV) in 10 and 20 dose presentations. The order is valued at ₹78.24 crore. This contract strengthens the company’s position as a key supplier of WHO-prequalified vaccines to global immunization programmes and adds to its existing long-term agreements with UNICEF for polio vaccine supplies. *Top stocks in the pharmaceuticals / vaccines industry:* Biocon, Zydus Lifesciences, and Hester Biosciences.

See More

Technical Analysis Panacea Biotec Limited.

The stock

has shown a powerful upward movement starting from early June 2026. It moved from around ₹440 to a high near ₹640 before entering a minor consolidation phase. Prior to this massive breakout the stock formed a clear long-term rounded bottom structure from November 2025 to April 2026 finding a solid floor near the ₹300–₹320 zone. The stock is currently trading at ₹565.65. After hitting its recent peak it has been consolidating sideways to flag-like which is healthy after an explosive move. Immediate Resistance the recent swing high near ₹640 acts as the immediate major resistance. A decisive daily close above this level could trigger the next leg of the rally. Immediate Support the ₹520–₹540 zone is acting as an immediate demand area where buyers are stepping in on dips. Major Base Support the ₹440 level the previous breakout point serves as strong structural support on the daily timeframe. For short-term buyers the stock shows strong bullish momentum and is currently consolidating healthily after a major breakout making any dips toward the ₹520–₹540 support zone a potential buying opportunity with a strict stop-loss below ₹500 for a target back near ₹640. For existing holders the structural view remains highly positive as long as the price sustains above the crucial breakout level of ₹440 so it is best to trail stop-losses and hold for a potential upside breakout above ₹640 toward ₹700+.

See More

Panacea Biotec Soars to Record High on Dengue Vaccine Breakthrough!

Shares of

surged as much as 17% intraday, extending gains for the sixth consecutive session and hitting a fresh all-time high of ₹647. The rally followed the company's announcement of the DENSTAR Project, a major initiative aimed at advancing the licensure of its dengue vaccine, DengiAll, across sub-Saharan Africa and supporting wider global adoption. The four-year program is funded under the Global Health European & Developing Countries Clinical Trials Partnership 3 Joint Undertaking, backed by the European Union. The development strengthens Panacea Biotec's global healthcare ambitions and has boosted investor optimism around its vaccine portfolio. Disclaimer: Investments in securities are subject to market risk. This is for educational purposes only. Investors must verify information before investing and consider their financial position & risk profile.

See More

Rounding bottom breakout

🚀 Panacea Biotec Extends Rally, Nears All-Time High

remained in strong momentum after Thursday’s bulk deal-driven surge, with the stock hitting the 20% upper circuit and extending gains on the Friday’s session. The stock climbed to ₹577.65, marking a fresh 52-week high and moving within touching distance of its all-time high of ₹581.90 recorded in May 2025. The rally follows a bulk deal in which OHM Investment Corporation acquired 3.14 lakh shares, representing a 0.51% stake, for ₹15.52 crore at ₹493.07 per share. The buying interest has significantly boosted investor sentiment, with the stock gaining more than 30% on a weekly basis, making it one of the standout performers in the small-cap healthcare space. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.

See More

Panacea Biotec (Weekly Chart) – Technical Analysis

1. Pattern Identification The stock has formed a large Cup & Handle breakout pattern on the weekly timeframe. The cup spans from the 2025 highs around ₹470–480, followed by a prolonged correction and rounded recovery. The recent consolidation around ₹320–430 acted as the handle. This week price has delivered a strong breakout candle above the neckline. This is one of the more reliable bullish continuation/reversal patterns when it appears after a long consolidation phase. 2. Entry / Retest Zones Aggressive Entry ₹460–480 Suitable while the stock remains above the breakout zone. Conservative Entry Wait for a pullback toward: ₹450–470 Neckline retest A successful retest of the breakout area would provide a lower-risk entry. 8. Probability View 1–3 months: Bullish 3–6 months: Strong Bullish 6–12 months: Potential move toward ₹600–700 if the breakout sustains

See More